Anti AI new "weapon"! China's first single HIV treatment compound preparation on the market

Source: xinhuanet.com January 24, 2018 recently, GSK announced that its holding joint venture company, Viiv The new generation of integrase inhibitor, dotilavir, is the core of the single-chip compound preparation of healthcare1, which is listed in the mainland of China This is also the first single-chip compound preparation of a complete treatment scheme in the field of HIV treatment in the mainland of China, which will make HIV treatment more convenient and efficient According to the data of early treatment and persistence in treatment of AIDS, by the end of October 2017, 746000 HIV infected and AIDS patients were reported alive and 229000 were reported dead At the end of 2016, 495000 people were receiving antiviral treatment
On January 19, 2017, the general office of the State Council issued the 13th five year plan of action for China's prevention and control of AIDS, which proposed to achieve "more than 90% of the infected and patients who have been diagnosed and know their own infection status", "more than 90% of the infected and patients who meet the treatment conditions receive antiviral treatment", "more than 90% of the infected and patients who have received antiviral treatment" The success rate of treatment is more than 90% "In order to achieve the" three 90% "goals as soon as possible, it needs the joint efforts of doctors, enterprises, governments, social organizations and other parties Among them, it is the responsibility of doctors to choose the right medicine for the infected and patients, help them to treat as early as possible and adhere to the treatment " Professor Wu Hao, director of the infection center of Youan Hospital Affiliated to Capital Medical University, said that regular antiviral treatment for infected people as early as possible could not only control the deterioration of the disease, but also reduce the chance of transmitting the virus to others "The ideal antiviral drugs should have the characteristics of high efficiency, good tolerance, high resistance barrier, low adverse events, easy to take and less interaction with other drugs As a single compound preparation of a complete treatment plan, dotiapramib tablets can be taken once a day without considering the food effect, which can reduce the drug burden, improve the treatment compliance and improve the quality of life of the infected people " According to Professor Zhang Fujie, director of clinical and research center of infection in Beijing Ditan Hospital, Capital Medical University, the listing of new drugs is a great progress of antiviral treatment in China "At present, the global antiviral treatment is gradually entering the era of integrated enzyme inhibitors, and fixed dose compound preparations have become the trend of future treatment." Zhang said It is reported that the new drug is a three in one compound drug with DTG as the core, which has been approved and listed in 50 countries and regions, and recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line preferred treatment drug for the treatment of HIV infected people As a global healthcare company, GSK has brought innovative treatment programs for HIV infected people in China since 1999 In 2017, dotiravir, a new HIV treatment drug, was launched in China "Improving the accessibility of innovative drugs is a clear strategy for us to fulfill our commitment of" based on China, work together with China, and serve China " Wei Liansheng, general manager of GSK China's prescription medicine and vaccine department, said, "we are working with a number of organizations to carry out a number of projects, including AIDS medical personnel training, as well as disease prevention and education, so as to better support and help people living with HIV." According to Dr Xu Ding, vice president of government affairs and communication of GSK, since 2016, GSK and the Chinese Preventive Medicine Association (CPMA) have worked together to cultivate talents in the field of AIDS medicine, as well as AIDS prevention and education projects GSK also funded the public welfare organization Beijing Red Ribbon house to carry out a series of project activities focusing on professional training and disease advocacy, and invested millions of yuan to support the "red ribbon Health Ambassador youth campus trip", aiming to make the whole society, especially young students, further understand the importance of AIDS prevention and control work and curb the AIDS epidemic through a series of publicity and education activities 。
"In 2016, GSK established the Institute of infectious diseases and public health in Beijing and signed a memorandum of strategic cooperation with Tsinghua University The Institute is responsible for leading the research and development of new infectious diseases drugs in China by GSK core, including drugs for HIV prevention and multi drug resistant bacterial infection treatment In the future, more innovative drugs in the field of HIV treatment will be introduced into the Chinese market " "AIDS is a major public health problem for China and even the world, and this disease field is also one of the key global R & D strategies of GSK," Xu said We are committed to constantly developing innovative drugs, breaking through existing treatment programs, promoting the development of AIDS prevention and control, and constantly introducing innovative AIDS treatment drugs to China "